Differential sensitivity of histone acetylation in nitrogen-mustard sensitive and resistant cells. Relation to drug uptake, formation and repair of DNA-interstrand cross-links.
Cultivation of Ehrlich-ascites tumor cells in the presence of N-mustard leads to a selection of cells with a defective choline carrier. As N-mustard employs the choline carrier for transport, this results in reduced drug uptake and in a decrease in drug sensitivity which is specific for N-mustard. Walker carcinoma cells with a stable pleiotropic resistance to a variety of alkylating agents and adriamycin exhibit no evidence for an impaired drug transport and show the same frequency of DNA-interstrand cross-links as the sensitive parental line. Both sensitive and resistant Walker cells exhibit equal capacities for repair of N-mustard induced DNA-interstrand cross-links. The inhibition of histone acetylation by N-mustard, however, was found to be significantly lower in the resistant Walker or Ehrlich cells compared to sensitive counterparts. Although the difference between N-mustard concentrations leading to half maximal inhibition of histone acetylation in sensitive and resistant cells is considerably smaller than the difference between N-mustard doses required for half maximal inhibition of cell proliferation the data suggest that--besides DNA-DNA cross-linking--the inhibition of histone acetylation has to be considered as an important alternative mechanism responsible for the cytotoxic activity of alkylating agents. Inhibition of histone acetylation is not due an accelerated deacetylation and is predominantly expressed in chromatin fractions soluble in 0.1 M NaCl after digestion with micrococcal nuclease.
Helliger
W
W
Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Austria.
Hofmann
J
J
Maly
K
K
Doppler
W
W
Hermann
B J
BJ
Höck
W
W
Puschendorf
B
B
Grunicke
H
H
D000107:Acetylation; D000818:Animals; D002279:Carcinoma 256, Walker / Q000378:metabolism; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism*; D002699:Chlorambucil / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D004247:DNA / Q000187:drug effects; D004351:Drug Resistance; D006657:Histones / Q000378:metabolism*; D008466:Mechlorethamine / Q000378:metabolism*; D051381:Rats; D014407:Tumor Cells, Cultured / Q000378:metabolism
D006657:Histones; D002699:Chlorambucil; D008466:Mechlorethamine; D003520:Cyclophosphamide; D004247:DNA